atacicept   Click here for help

GtoPdb Ligand ID: 9517

Synonyms: TACI-Fc | TACI-Ig
Immunopharmacology Ligand
Comment: Atacicept is a recombinant fusion protein that was designed to inhibit B cells, and which was investigated as an intervention in autoimmune diseases [2]. Mechanistically atacicept neutralises the function of two important B-cell activating factors, BAFF (BLyS) and APRIL. Structurally atacicept contains the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a modified Fc from human IgG1 [4]. One of the important functions of these two factors in autoimmune disease is their ability to induce proliferation of plasma cells and thus increase Ig production, in particular the production of destructive anti-self antibodies. However, this modality has proven ineffective in autoimmune diseases in clinical studies. As of June 2021 atacicept was being deployed for IgA nephropathy.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for atacicept is claimed in patent WO2002094852 [8].
No information available.
Summary of Clinical Use Click here for help
Atacicept was investigated for clinical efficacy in a range of autoimmune conditions e.g. SLE [3], rheumatoid arthritis [10] and optic neuritis (a demyelinating inflammation of the optic nerve) [9]. These trials have largely been unsuccessful., however Vera Therapeutics believe it may have potential for IgA nephropathy (based on results from Merck's trial NCT02808429 in patients with kidney disease IgA nephropathy), and as of January 2021 they were planning on taking atacicept forward for this indication.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00642902 A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) Phase 2 Interventional EMD Serono 1,5
NCT02808429 Efficacy and Safety of Atacicept in IgA Nephropathy Phase 2 Interventional EMD Serono
NCT01972568 Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus Phase 2 Interventional EMD Serono 6-7
NCT00624338 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Phase 2/Phase 3 Interventional EMD Serono 4
NCT04716231 Atacicept in Subjects With IgA Nephropathy Phase 2 Interventional Vera Therapeutics, Inc.